"No official pricing for such therapies has yet been published, but a figure of $649,000 for a one-off treatment has been deemed justifiable for young patients with leukemia by the UK's National Institute for Health and Care Excellence. "Just last week, Kaiser Health News ran a report on the potential pricing of the Novartis version of the therapy, and sources told it that it would 'cost a fortune,' proving to be 'a quantum leap more expensive than other cancer drugs,'" Tech Review notes. The cost to patients, at least in the beginning, could be massive. ![]() 29 whether to approve Kite's CAR-T, axi-cel, for treatment of adults with advanced lymphoma.įor MIT's Technology Review, the huge price tag attached to the acquisition is a "clear sign" that Kite's genetic engineering approach to developing cancer therapeutics is the wave of the future.īut there may also be a problem, Tech Review says. Kite Pharma a BUY with a target price of 85.30. If approved, these drugs are expected to generate billions of dollars in profits. Diluted Shares Outstanding 49,624,622 2017 EPS (Est.) -5.67 2016 EPS (Est.) -4.46 2015 EPS -2.33 2014 EPS -1.91. Kite is one of the leading players in the emerging field of CAR-T therapy, and is competing with Novartis, Juno Therapeutics, and Bluebird bio to get the first approved therapy to market, the newswire adds. ![]() At $180 a share, that price represents a 29.4 percent premium over Kite's closing share price on Friday, according to Reuters. Gilead Sciences just paid $11.9 billion to acquire Kite Pharma. Advances in Clinical Genomics Profiling.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |